KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Inventory (2016 - 2025)

Gilead Sciences (GILD) has disclosed Change in Inventory for 17 consecutive years, with $123.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory fell 45.58% year-over-year to $123.0 million, compared with a TTM value of $1.0 billion through Dec 2025, up 143.19%, and an annual FY2025 reading of $1.0 billion, up 143.19% over the prior year.
  • Change in Inventory was $123.0 million for Q4 2025 at Gilead Sciences, down from $515.0 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $515.0 million in Q3 2025 and bottomed at -$70.0 million in Q3 2021.
  • Average Change in Inventory over 5 years is $130.2 million, with a median of $90.0 million recorded in 2022.
  • The sharpest move saw Change in Inventory crashed 369.23% in 2021, then skyrocketed 2925.0% in 2023.
  • Year by year, Change in Inventory stood at -$35.0 million in 2021, then surged by 888.57% to $276.0 million in 2022, then increased by 11.23% to $307.0 million in 2023, then fell by 26.38% to $226.0 million in 2024, then plummeted by 45.58% to $123.0 million in 2025.
  • Business Quant data shows Change in Inventory for GILD at $123.0 million in Q4 2025, $515.0 million in Q3 2025, and $175.0 million in Q2 2025.